Search This Blog

Thursday, November 9, 2023

PDS: HPV16-Positive Cancer Patients 75% Survival at 36 Months

 

  • 75% of immune checkpoint inhibitor (ICI) naïve patients remain alive at 36 months; published median overall survival (OS) in similar patients is 7-11 months

  • 12-month survival rate in ICI resistant patients is 72%

  • Median OS in ICI resistant patients is approximately 20 months; published median OS is 3.4 months

Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)